Key facts
- This page summarizes Kamil Ali-Jackson's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 05 Jan 2022, 15:33.
Kamil Ali-Jackson - 03 Jan 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- ACRS
- Reported as of
- 03 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2022, 15:33:56 UTC
- Prior SEC filing
- 17 Dec 2021
- Next SEC filing
- 23 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kamil Ali-Jackson filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 05 Jan 2022.
Change
- Previous filing in this sequence was filed on 17 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,875
- Change %
- +3.4%
- Price
- Shares after
- 118,571
- Date
- 03 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
ACRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +27,905
- Change %
- +24%
- Price
- Shares after
- 146,476
- Date
- 03 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
ACRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +6,638
- Change %
- +4.5%
- Price
- Shares after
- 153,114
- Date
- 03 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
ACRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +7,100
- Change %
- +4.6%
- Price
- Shares after
- 160,214
- Date
- 03 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACRS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,875
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,875
- Exercise price
- Footnotes
- F1, F2, F3
ACRS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -27,905
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 34,350
- Exercise price
- Footnotes
- F1, F2, F4
ACRS
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -6,638
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,914
- Exercise price
- Footnotes
- F1, F2, F5
ACRS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -7,100
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 28,400
- Exercise price
- Footnotes
- F1, F2, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Kamil Ali-Jackson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
Footnote F2
Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited.
Footnote F3
The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
Footnote F4
The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
Footnote F5
The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
Footnote F6
The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.